Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SEP-4199 for bipolar I depression
2018-000103-16Phase 2Completed
- Sponsor
- Sunovion
- Start
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of SEP-4199 in bipolar I disorder (3 arms), sponsored by Sunovion. Primary endpoint: Change from baseline in MADRS total score at Week 6. Started Jul 2018; status: completed.
02
Drugs
SEP-4199
03
Conditions
bipolar I disorder
Beyond the preview
Go deeper on 2018-000103-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000103-16.